Content specific to this active ingredient… Drug Information Prescribing and patient information from leading authorities Drug Master Files Type 2 master files on file at the FDA Safety Information For prescription drugs containing this active ingredient Exclusivity Patent and market exclusivity data Federal Register FR search results for this API FDA Approved Labelling Information found in this drug's package inserts Research Links Chemical identification and research citations Title 21 Code of Federal Regulations FDA regulations for this API

FDA Approval Activities for this Drug… Triamterene and Hydrochlorothiazide Capsules USP, 37.5 mg/25 mg. Barr, ANDA 74-970 1/6/98 3/15/99 Triamterene and Hydrochlorothiazide Capsules USP, 37.5 mg/25 mg, Duramed ANDA 75-052 | Dyazide (hydrochlorothiazide/triamterene) Capsules, GlaxoSmithKline, Labeling Revision | Triamterene and Hydrochlorothiazide Capsules, Mylan Pharma, Control Suppl. | Dyazide (hydrochlorothiazide and triamterene) Capsules, GlaxoSmithKline, Labeling Revision | Dyazide (hydrochlorothiazide and triamterene) Capsules, GlaxoSmithKlein, Labeling Revision | Maxzide (hydrochlorothiazide and triamterene) Tablets, Mylan Pharmaceuticals Inc., Labeling Revision ^ FDA's latest approval appears at the bottom of this list. ^                                                                       A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | For Industry | DMF Index | Pharma Job Search | Pharma Company News | Best Phone © 2012 Betterchem.com